Excessive Daytime Sleepiness Market: Epidemiology, Therapies, Companies, DelveInsight | Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, Suven Life Sciences, NLS Pharma Ltd, XWPharma, Take

Excessive daytime sleepiness therapies, such as WAKIX (pitolisant), XYREM (sodium oxybate), XYWAV (calcium, magnesium, potassium, and sodium oxybates), and others, are expected to boost the Excessive daytime sleepiness Market in the upcoming years.

DelveInsight has launched a new report on "Excessive daytime sleepiness - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Excessive daytime sleepiness, historical and forecasted epidemiology as well as the Excessive daytime sleepiness market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Excessive daytime sleepiness market report @ https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Excessive daytime sleepiness Market Report:

Excessive daytime sleepiness (EDS) is marked by difficulty staying awake and alert during key waking hours, leading to unintentional sleep or sleep at inappropriate times. EDS is frequently linked to various health conditions, including metabolic, cardiovascular, neurological, and psychiatric disorders, where poor sleep habits and sleep deprivation contribute to disability and a heightened risk of mortality.
According to DelveInsight estimates, in 2023, approximately 3.9 million diagnosed cases of excessive daytime sleepiness were reported in the United States. This number is expected to increase by 2034, driven by greater focus on raising disease awareness, better differentiation from conditions such as fatigue, and increasing recognition of lifestyle and mental health factors like stress and depression.
In the EU4 and the UK, there were around 2 million diagnosed prevalent cases of excessive daytime sleepiness in 2023. Germany had the highest number of diagnosed cases, followed by France. While excessive daytime sleepiness is a prevalent issue in Europe, affecting a large number of individuals and potentially disrupting daily life and overall well-being, there is limited data on disease diagnosis, as well as a high rate of misdiagnosis, particularly with conditions like obstructive sleep apnea (OSA) and bipolar disorder.
The Excessive Daytime Sleepiness market across the 7MM was valued at approximately USD 6,227 million in 2023, with expectations for growth throughout the forecast period (2024-2034). In the United States, the market size for Excessive Daytime Sleepiness treatments was USD 4,690 million in 2023. Major players in the market include SUNOSI, WAKIX, XYREM, XYWAV, and others. In 2023, the market sizes for XYREM and WAKIX were USD 1,163 million and USD 565 million, respectively, across the 7MM.
XYWAV, a lower-sodium alternative to XYREM, was approved in 2020 for treating Excessive Daytime Sleepiness in narcolepsy, generating USD 1,007 million in revenue in 2023. In Japan, the Excessive Daytime Sleepiness market generated approximately USD 382.8 million in 2023, with anticipated growth by 2034.
AXS-12 (reboxetine), expected to launch in the US market by 2025 for Excessive Daytime Sleepiness in narcolepsy, has the potential to gain a strong presence in the market due to the expiration of patents for existing therapies. The drug is projected to have moderate uptake, reaching its peak by its seventh year.
In June 2024, the FDA approved Harmony Biosciences' Wakix (pitolisant) for treating EDS in children aged 6 years and older with narcolepsy. This marks the first non-scheduled medication approved for pediatric narcolepsy, offering a new treatment option for younger patients.
In October 2024, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release sodium oxybate formulation, for treating EDS and cataplexy in children aged 7 years and older with narcolepsy. Lumryz is notable for its once-nightly dosing, potentially improving adherence compared to twice-nightly alternatives.
Key Excessive daytime sleepiness companies such as Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, Suven Life Sciences, NLS Pharma Ltd, XWPharma, Takeda Pharmaceutical, and others are evaluating new drugs for Excessive daytime sleepiness to improve the treatment landscape.
Promising Excessive daytime sleepiness therapies include WAKIX (pitolisant), XYREM (sodium oxybate), XYWAV (calcium, magnesium, potassium, and sodium oxybates), and others.

Excessive daytime sleepiness Overview

Myositis refers to inflammation of the muscles and is commonly linked with a group of inflammatory muscle diseases, including polymyositis, dermatomyositis, cancer-associated myositis, juvenile dermatomyositis, overlap myositis, and inclusion body myositis (IBM). While *myositis* specifically involves inflammation, *myopathy* is a broader term encompassing any disease or disorder of the muscles, including but not limited to myositis.

This rare condition can impact not only the muscles but also various other organs, often resulting in significant reductions in quality of life. According to the American College of Rheumatology, inflammatory myopathies are autoimmune diseases in which the immune system mistakenly attacks healthy muscle tissue. Dermatomyositis and polymyositis are the most frequently occurring types within this group.

Excessive daytime sleepiness Market Outlook

The assessment and management of excessive daytime sleepiness focus on identifying and addressing underlying conditions, such as narcolepsy, Parkinson's disease, obstructive sleep apnea (OSA), idiopathic hypersomnia (IH), and bipolar disorder. The primary treatment approach involves supportive care and approved therapies to relieve symptoms. Supportive treatments include armodafinil (the R-enantiomer of modafinil), amphetamines, methamphetamine, dextroamphetamine, and methylphenidate.

Excessive sleepiness is typically treated with amphetamine-like central nervous system (CNS) stimulants, such as methylphenidate, modafinil, and its R-enantiomer, armodafinil, which are wake-promoting substances not related to amphetamines. The American Academy of Sleep Medicine (AASM) has recently recommended sodium oxybate, a short-acting sedative with an unknown mechanism of action, as a first-line treatment for excessive daytime sleepiness and cataplexy. Commonly used amphetamine-like medications include methylphenidate, methamphetamine, D-amphetamine (all Schedule II substances), and mazindol (a Schedule IV substance). The use of stimulants in narcolepsy has been guided by AASM practice standards.

Provigil (modafinil), launched by Cephalon in 1999, is approved for treating excessive sleepiness related to narcolepsy, OSA, and shift work disorder (SWD). It is available in more than 30 countries, including the US, France, the UK, Ireland, Italy, and Germany, for the treatment of excessive daytime sleepiness in narcolepsy. In January 2007, modafinil was approved by the Japanese PMDA for excessive daytime sleepiness due to narcolepsy. It was later approved for OSA-related sleepiness with continuous positive airway pressure (CPAP) treatment in 2011, and for idiopathic hypersomnia in 2020.

Nuvigil (armodafinil), the R-isomer of modafinil, was introduced in June 2009 and is indicated for excessive sleepiness associated with narcolepsy, OSA, and SWD.

In March 2019, the US FDA approved Sunosi (solriamfetol) for excessive daytime sleepiness linked to narcolepsy or OSA. Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults with excessive daytime sleepiness due to narcolepsy or OSA. In January 2020, the drug received EU marketing authorization for the same conditions and is also being evaluated for pediatric use. Sunosi is the only licensed treatment in Europe for excessive daytime sleepiness in adults with OSA.

Discover how the Excessive daytime sleepiness market is rising in the coming years @ https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Marketed Excessive daytime sleepiness Drugs
WAKIX/ OZAWADE (pitolisant): Bioprojet Pharma/Harmony Biosciences
SUNOSI (Solriamfetol): Jazz Pharmaceuticals
Excessive daytime sleepiness Emerging Drugs
AXS-12 (Reboxetine): Axsome Therapeutic
Samelisant (SUVN-G3031): Suven Life Sciences

Scope of the Excessive daytime sleepiness Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Excessive daytime sleepiness Companies: Bioprojet Pharma, Harmony Biosciences, Jazz Pharmaceuticals, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, Suven Life Sciences, NLS Pharma Ltd, XWPharma, Takeda Pharmaceutical, and others
Key Excessive daytime sleepiness Therapies: WAKIX (pitolisant), XYREM (sodium oxybate), XYWAV (calcium, magnesium, potassium, and sodium oxybates), and others
Excessive daytime sleepiness Therapeutic Assessment: Excessive daytime sleepiness current marketed and Excessive daytime sleepiness emerging therapies
Excessive daytime sleepiness Market Dynamics: Excessive daytime sleepiness market drivers and Excessive daytime sleepiness market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Excessive daytime sleepiness Unmet Needs, KOL's views, Analyst's views, Excessive daytime sleepiness Market Access and Reimbursement

To know what's more in our Excessive daytime sleepiness report, visit https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Excessive daytime sleepiness Market Report:
Excessive daytime sleepiness market report covers a descriptive overview and comprehensive insight of the Excessive daytime sleepiness Epidemiology and Excessive daytime sleepiness market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Excessive daytime sleepiness market report provides insights into the current and emerging therapies.
The Excessive daytime sleepiness market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Excessive daytime sleepiness market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Excessive daytime sleepiness market.

Got queries? Click here to know more about the Excessive daytime sleepiness market Landscape https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Excessive daytime sleepiness Patient Share (%) Overview at a Glance
5. Excessive daytime sleepiness Market Overview at a Glance
6. Excessive daytime sleepiness Disease Background and Overview
7. Excessive daytime sleepiness Epidemiology and Patient Population
8. Country-Specific Patient Population of Excessive daytime sleepiness
9. Excessive daytime sleepiness Current Treatment and Medical Practices
10. Unmet Needs
11. Excessive daytime sleepiness Emerging Therapies
12. Excessive daytime sleepiness Market Outlook
13. Country-Wise Excessive daytime sleepiness Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Excessive daytime sleepiness Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Excessive daytime sleepiness Market Outlook 2034 https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Excessive daytime sleepiness Pipeline Insights, DelveInsight

"Excessive daytime sleepiness Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Excessive daytime sleepiness market. A detailed picture of the Excessive daytime sleepiness pipeline landscape is provided, which includes the disease overview and Excessive daytime sleepiness treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.